ライフサイエンスコーパス: postdose

1 t had been converted to 5-MTHF after 15 min (postdose).

2 e plasma isotopic-ratio measurement (18-25 d postdose).

3 antly reduced blood glucose levels up to 6 h postdose.

4 antified in individual brain sections 45 min postdose.

5 Elevation of IGF-1 levels was observed postdose.

6 therapies or colectomy during the first year postdose.

7 olic equivalents [METS], Bruce protocol) 1 h postdose.

8 f (2)H(2)- and (13)C(5)-labeled folates 48 h postdose.

9 d until the effect was fully reversed by 3 h postdose.

10 level of inhibition remaining at 40% at 12 h postdose.

11 patients who were HCV RNA-negative 76 weeks postdosing.

12 ry relative to maternal serum enrichment 2 h postdosing.

13 days 1 (4, 8, and 12 hours), 2, 4, 7, and 14 postdosing.

14 2,000-fold over the IC(90) value for 7 days postdosing.

15 ses and were generally undetectable by 24-hr postdosing.

16 ta and correlated with serum D:H at 3 or 6 d postdosing.

17 inol equilibrated with the body pool by 20 d postdosing.

18 nitoring (approximately 16 h predose to 24 h postdose); 12-lead electrocardiograms (ECGs); clinical c

19 y (D) 43, and D91 for GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and 1 month postprimar

20 ometric mean concentrations from baseline to postdose 3 showed significant increases in antibody leve

21 ths, significant increases from predose 4 to postdose 4 (GMFR range, 3.00-6.97), and little change af

22 dian peak plasma concentrations at 1-2 hours postdose and mean terminal half-life of 12-15 hours.

23 In all trials, urine was collected 24-36 h postdosing and the isotopic labeling of urinary folates

24 were temporally similar with respect to time postdose (and the postdose timing of an NSVT event in a

25 timeline for vitamin B-12 administration and postdose assessment.

26 SB1518 inhibited JAK2 signaling at 4 hours postdose at all levels.

27 lated to dose, plasma concentration, or time postdose at which samples were obtained, but was positiv

28 the next dose of tiotropium), peak, and 6-h postdose average FEV(1) and FVC, and in PEFR, without a

29 Twenty minutes postdose, beta-glucocerebrosidase activity increased ove

30 roemulsion (CsA-ME; Neoral) exposure 2 hours postdose (C2) has been reported to optimize the efficacy

31 During the first 24 h postdose, cases excreted less (f1.gif" BORDER="0"> +/- S

32 under the curve (AUC), maximum concentration postdose (Cmax), minimum concentration postdose (Cmin),

33 ation postdose (Cmax), minimum concentration postdose (Cmin), time to maximum concentration (Tmax).

34 c study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentratio

35 Targeting 2-hr postdose cyclosporine (C2) levels to 1,000 to 1,700 mg/d

36 nstrument was administered predose and daily postdose Days 1-6.

37 hepatic CDK1 content by 1.9-6.3-fold through postdosing days 1-5.

38 Postdosing dual-isotope single photon emission computed

39 ma samples were collected at 6, 12, and 24 h postdose during the first day and at 15 time points duri

40 s were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease o

41 A significantly greater increase in 2-hour postdose FEV(1) at the endpoint was observed after treat

42 lergen challenge was performed on day 6 (2 h postdose), followed by methacholine challenge (day 7), a

43 ssayed at baseline and at 1, 4, and 24 hours postdose in cycle 1.

44 adduct was also identified in 96 h and 168 h postdose in vivo cynomolgus monkey plasma.

45 ncrease in serum lactate from 24 to 72 hours postdosing in the treated subjects alone (P< 0.005).

46 pirin on repeated exposure, extension of the postdosing interval, or addition of aspirin to their pla

47 The proportion of patients with any single postdose intraocular pressure >/=30 mmHg was 9.2%, 6.6%,

48 One hour postdose liver, adipose, and brain tissue 11beta-HSD1 in

49 ibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (+/-SD)]: clopidogrel 64% [+/-22%], AZD61

50 Serum D:H 3 d postdosing might be used as an early indicator of total

51 However, adverse events, postdose nausea with high-dose azithromycin, effectivene

52 e no differences between treatment arms with postdose nausea, vomiting, or other adverse events.

53 interleukin-6 levels were detected 1 to 6 hr postdosing only at the three highest doses and were gene

54 5)]PteGlu(1) excreted during the second 24 h postdose or when the data were averaged over 48 h.

55 Postdose PC(20)FEV(1) results met standard bioassay stud

56 by 1.88-fold compared to baseline during the postdosing period (95% CI, 1.03- to 3.43-fold; P = .04).

57 d to nondeuterated retinol (D:H) at 3 or 6 d postdosing predicted body stores, and 3) the ability of

58 stimates of body stores and serum D:H at 3 d postdosing (r = -0.75, P = 0.002); at 6 d postdosing, th

59 565 +/- 149 minutes and 581 +/- 150 minutes postdose, respectively.

60 Predose and postdose safety assessments included orthostatic vital s

61 subset of individuals (n = 6) with immediate postdose sampling (HIV-1 RNA increase, 2.96-fold; 95% CI

62 ice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given.

63 elation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help t

64 The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L)

65 Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated g

66 ach dose), 24-h urine TMAO, predose and 24-h postdose serum hsCRP, and plasma oxidized LDL were measu

67 A shorter time to the first postdose spontaneous bowel movement and a higher mean nu

68 o laxatives before enrollment, time to first postdose spontaneous bowel movement, and mean number of

69 Few children reported postdosing symptoms, with no differences in the frequenc

70 trolled vitamin A dosing trial with pre- and postdose testing of dark-adaptation threshold.

71 At 3 days postdosing, TFV-DP concentrations in peripheral blood mo

72 d postdosing (r = -0.75, P = 0.002); at 6 d postdosing, the correlation was weaker.

73 tarting from 5 days before chemotherapy (pre/postdoses, three/one or one/one) compared with only four

74 milar with respect to time postdose (and the postdose timing of an NSVT event in a monkey).

75 Both the pre- and postdosing tissue samples adjacent to tumors show no def

76 tment visit provided data from 8 to 12 hours postdose, to examine maintenance of effect.

77 patients given rhTPO by other schedules (pre/postdoses, two/two, one/three, zero/four, or four/zero)

78 Iron incorporation into red blood cells 14 d postdosing was similar (6.9 +/- 4.2% compared with 7.9 +

79 er samples taken from the microcosms at 24 h postdosing were used in acute toxicity tests with two st

80 egation in response to ADP between 2 and 8 h postdose with the level of inhibition remaining at 40% a

81 re measured in maternal blood collected 2 wk postdosing with oral (57Fe) and intravenous (58Fe) stabl